Volcano Corporation Announces Collaboration With Stanford University, Cardialysis and Cardiovascular Research SYS-CON Media
Volcano Corporation , Stanford University, Cardialysis and Cardiovascular Research Foundation (CRF) today announced a collaboration whereby Volcano has agreed to provide intravascular ultrasound (IVUS) catheters free of charge for use in pivotal Drug Eluting Stent (DES) clinical trials. This offer will be made available to stent manufacturers utilizing the core lab services of Stanford,
Volcano Corporation Announces Collaboration With Stanford University, Cardialysis and Cardiovascular Research PR Newswire via Yahoo! Finance
Volcano Corporation , Stanford University, Cardialysis and Cardiovascular Research Foundation today announced a collaboration whereby Volcano has agreed to provide intravascular ultrasound catheters free of charge for use in pivotal Drug Eluting Stent clinical trials.
Worried over heart attacks? Take to five vegetables Hindustan Times
While numerous studies in humans have shown that a high-vegetable diet is associated with a reduced risk of cardiovascular disease, as well as with reductions in blood pressure and increases in "good" cholesterol, a new research on animals suggests that increased vegetable consumption may reduce hardening of arteries, thus preventing heart attacks and strokes.
Increase in Diabetes and Obesity Numbers Driving Cardiovascular Drug Market Towards the $100 Billion Mark Business Wire via Yahoo! Finance
DUBLIN, Ireland----Research and Markets has announced the addition of Espicom Business Intelligence's new report: New Drug Futures: Cardiovascular Chapter to their offering.
SCAI president testifies before FDA on safety of drug-eluting stents EurekAlert!
(December 7, 2006 — WASHINGTON, DC) -- In testimony before the Food and Drug Administration (FDA), Gregory J. Dehmer, MD, president of the Society for Cardiovascular Angiography and Interventions (SCAI), today urged a review panel to evaluate new data on the safety of drug-eluting stents (DES) from the perspective of prior developments in the history of coronary intervention, and with an
Rheologics Establishes Scientific Advisory Board Market Wire via Yahoo! Finance
Rheologics, Inc., a subsidiary of Rheologics Technologies, Inc., the leader in the study of blood viscosity and its relationship to cardiovascular disease, is pleased to announce that the Company has established its Scientific Advisory Board with the appointment of nine members, including the following cardiologists, hematologists, as well as pharmaceutical and bioengineering specialists:
FDA Panel To Hear New Data From Kaiser Permanente Experts On Drug-eluting Heart Stents Medical News Today
On Friday, December 8th, Kaiser Permanente physicians will present new research based on Kaiser Permanente data gleaned from cardiovascular patients in the Colorado and Northern California regions to the Food and Drug Administration's committee looking into safety concerns being raised for patients treated with drug-eluting stents. [click link for full article]
CryoCath to present at 2006 RBC Capital Markets Health Care Conference CNW Group via Yahoo! Finance
CryoCath Technologies Inc. , the global leader in cryotherapy products to treat cardiovascular disease, today announced that Henri Vienneau, Interim President and CEO of the Company, will present on the "Close to the Heart: New Technology Solutions" panel at the 2006 RBC Capital Markets Health Care Conference in New York on Wednesday, December 13, at 8:00a.m.
Pfizer Halts Testing of New Drug RedNova
By Anthony Cronin, The Day, New London, Conn. Dec. 3--Pfizer Inc. said Saturday night that it would end clinical trials as well as the development of its much-anticipated torcetrapib compound because of increased risks of death and cardiovascular problems.
New Billing Code and Medicare Payment Recommendation Issued for Lp-PLA2 Testing Business Wire via Yahoo! Finance
SOUTH SAN FRANCISCO, Calif.----diaDexus, Inc., today announced that the American Medical Association has issued a unique Category I Current Procedural Terminology code for the measurement of lipoprotein-associated phospholipase A2 , a cardiovascular-specific inflammatory enzyme found in unstable, rupture-prone plaque.
cardiovascular: cardiovascular